Trial Profile
Prospective, Multicenter, Open-labeled, Phase I/II Study of the Efficacy and Safety of Copanlisib (BAY 80-6946) and Gemcitabine Combination in Patients With Relapsed/Refractory Peripheral T-cell or NK/T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Gemcitabine (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms COSMOS
- 09 Jun 2022 Status changed from active, no longer recruiting to completed.
- 19 Dec 2020 Results published in the Annals of Oncology
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association